Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Bad Ischl – page 10

307 clinical trials in Bad Ischl, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Bad Ischl at a glance
307
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

307 trials in Bad Ischl

Open in trial search

Parkinson's disease

Not yet recruiting

A study to test if BHV-8000 is effective and safe for adults with early Parkinson's disease

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ioflupane (123I)
  • Sponsor:Biohaven Therapeutics Ltd.

Partial seizures

Not yet recruiting

Study on the Effectiveness and Safety of BHV-7000 for Adults with Refractory Focal Onset Epilepsy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Narcolepsy

Not yet recruiting

Study on TAK-861 for Treating Narcolepsy with Cataplexy in Patients

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Oveporexton
  • Sponsor:Takeda Development Center Americas Inc.

Epidermolysis bullosa

Not yet recruiting

Study on ABCB5+ MSCs for Recessive Dystrophic and Junctional Epidermolysis Bullosa Patients

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:ALLO-APZ2-EB
  • Sponsor:Rheacell GmbH & Co. KG

Narcolepsy

Not yet recruiting

A Randomized, Double‑Blind Study of ORX750 versus Placebo for Excessive Daytime Sleepiness in Adults with Narcolepsy (Type 1 and Type 2)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ORX750
  • Sponsor:Centessa Pharmaceuticals UK Limited

Efficacy of neoadjuvant sacituzumab govitecan versus standard drug combination in patients with endocrine non‑responsive ER+/HER2‑negative early breast cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group

Adenocarcinoma pancreas+1

Not yet recruiting

Diagnostic Performance of [68Ga]Ga-HKG301 PET/CT with FAP-2286 in Patients with Pancreatic Adenocarcinoma and Invasive Lobular Breast Cancer

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:FAP-2286
  • Sponsor:Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH

Prostate cancer metastatic

Not yet recruiting

Study of saruparib plus AR inhibitor drug combination in men with metastatic hormone‑sensitive prostate cancer previously treated with docetaxel or Lu‑PSMA and PSA ≥0.2 ng/mL

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Astrazeneca AB

VEXAS syndrome

Not yet recruiting

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate
  • Sponsor:Glaxosmithkline Research & Development Limited

Adenocarcinoma pancreas

Not yet recruiting

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

Metastatic malignant melanoma+2

Not yet recruiting

Methoxsalen (ECP) versus drug combination for steroid‑refractory immune‑related colitis or hepatitis in metastatic melanoma on checkpoint therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Therakos Europe Limited

Myasthenia gravis

Not yet recruiting

Efficacy and Safety of DNTH103 in Adults with Generalized Myasthenia Gravis: A Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:DNTH103
  • Sponsor:Dianthus Therapeutics Inc.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Bad Ischl

What the registry says about research in the country

01 Respiratory Medicine

Innovative research focused on Chronic Obstructive Pulmonary Disease (COPD) treatment optimization through combination therapy approaches. Studies explore the effectiveness of triple therapy combinations including bronchodilators and anti-inflammatory medications.

  • Triple Therapy Evaluation
  • Cardiopulmonary Outcomes
  • Treatment Optimization

Clinical investigations aim to improve patient outcomes in moderate to severe COPD cases.

02 Pulmonary Therapeutics

Advanced research examining the efficacy of benralizumab in treating patients with moderate to very severe COPD. Focus on reducing exacerbation frequency in patients with elevated blood eosinophils.

  • Exacerbation Management
  • Targeted Therapy
  • Disease Control

Studies specifically target patients with a history of frequent COPD exacerbations.

03 Respiratory Care Innovation

Development of new therapeutic approaches using metered-dose inhalers for COPD management. Research combines multiple active ingredients to achieve optimal bronchodilation and anti-inflammatory effects.

  • Medication Delivery Systems
  • Combination Therapies
  • Treatment Efficacy

Emphasis on improving delivery methods and treatment effectiveness for respiratory conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.